Keros Therapeutics, Inc.
NASDAQ:KROSBiotechnology
+$0.13 today
- Market cap
- $235.49M
- Beta
- 0.96
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$2.29
Volume 0.55M
Average 0.36M
KROS Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Keros Therapeutics, Inc.NASDAQ: KROS
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization grows, but more slowly than its trailing trend
Q1 FY2026 depreciation & amortization of $403K rose 17.2% year over year, behind the +21.0% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 0.8% from the prior quarter. Over 3 fiscal years it compounded at +30.8% a year.
Context
- Depreciation & amortization amounted to 0.6% of revenue in FY2025, down 34.0 pp from a year earlier.
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +17.2% toward the trailing-twelve-month pace of +21.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 1.51M USD
- Year-over-year change
- +22.8%
- 4-year CAGR
- +41.4%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.51M | +22.8% |
| FY2024 | 2024-12-31 | 1.23M | +50.8% |
| FY2023 | 2023-12-31 | 815K | +20.9% |
| FY2022 | 2022-12-31 | 674K | +78.3% |
| FY2021 | 2021-12-31 | 378K | — |
Depreciation & Amortization vs competitors
How KROS compares with its peers on the latest reported figures
- KROS's LTM Mar 2026 depreciation & amortization of $1.57M is the 6th largest of the 10 companies compared; the peer median is $1.71M.
- Its year-over-year change of +21.0% is the 4th highest of 10, against a peer median of +11.1%.
- Depreciation & amortization amounts to 4.7% of revenue for KROS, versus a peer median of 2.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $15.52M | -3.0% | +6.5% | 17.7% | |
| LTM Mar 2026 | $11.4M | -12.6% | -3.6% | 620.8% | |
| LTM Mar 2026 | $3.08M | +114.9% | +496.0% | — | |
| LTM Mar 2026 | $2.41M | -1.0% | +34.3% | 0.8% | |
NAGENiagen Bioscience Inc | LTM Mar 2026 | $1.71M | +16.6% | -8.4% | 1.3% |
| LTM Mar 2026 | $1.57M | +21.0% | +30.8% | 4.7% | |
| LTM Mar 2026 | $1.03M | -39.0% | -38.3% | 2.9% | |
| LTM Mar 2026 | $997K | +3223.3% | — | 2.0% | |
| LTM Mar 2026 | $481K | +11.1% | -33.4% | — | |
| LTM Mar 2026 | $112K | +33.3% | -34.1% | — | |
| Peer median (excluding KROS) | $1.71M | +11.1% | -6.0% | 2.5% | |
Competitors are the stored peer set for KROS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (58.74M) | (104.68M) | (152.99M) | (187.35M) | 87.01M |
| Depreciation & Amortization | 378K | 674K | 815K | 1.23M | 1.51M |
| Deferred Income Tax | 46K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 11.72M | 18.68M | 28.76M | 34.87M | 28.7M |
| Change in Working Capital | (16.07M) | 14.31M | (2.65M) | (11.44M) | (12.11M) |
| Accounts Receivables | (18M) | 18M | (143K) | (2.6M) | (825K) |
| Inventory | 1.04M | 0 | (4.51M) | 0 | 0 |
| Accounts Payables | 1.49M | (408K) | 1.61M | (249K) | (3M) |
| Other Working Capital | (597K) | (3.28M) | 384K | (8.59M) | (8.29M) |
| Other Non-Cash Items | 520K | 953K | 1.56M | 1.82M | 2.4M |
| Operating Cash Flow | (62.15M) | (70.06M) | (124.51M) | (160.87M) | 107.51M |
| Capital Expenditures | (1.02M) | (1.24M) | (2.46M) | (1.93M) | (1.55M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (1.02M) | (1.24M) | (2.46M) | (1.93M) | (1.55M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 28.17M | 119.58M | 175.83M | 380.13M | (3.47M) |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | (375M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 379K | 731K | 3.13M | 11.69M | 0 |
| Financing Cash Flow | 28.55M | 120.31M | 178.96M | 391.82M | (378.47M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (34.62M) | 49.01M | 51.98M | 229.02M | (272.52M) |
| Free Cash Flow | (63.17M) | (71.3M) | (126.97M) | (162.8M) | 105.95M |
Keros Therapeutics, Inc.
NASDAQ:KROS
Intrinsic Alpha fair value
Locked
Current Price
$12.00
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.